Online citations, reference lists, and bibliographies.
← Back to Search

Phase II Study Of A Liposome-entrapped Cisplatin Analog (L-NDDP) Administered Intrapleurally And Pathologic Response Rates In Patients With Malignant Pleural Mesothelioma.

C. Lu, R. Pérez-Soler, B. Piperdi, G. Walsh, S. Swisher, W. Smythe, H. Shin, J. Ro, L. Feng, M. Truong, A. Yalamanchili, G. López-Berestein, W. Hong, A. Khokhar, D. Shin
Published 2005 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PURPOSE To determine pathologic response rates to liposome-entrapped cis-bisneodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) administered intrapleurally in patients with malignant pleural mesothelioma. PATIENTS AND METHODS Thirty-three patients with malignant pleural mesothelioma and free-flowing pleural effusions received intrapleural L-NDDP once every 3 weeks at a dose of 450 mg/m2. Thoracoscopic evaluation with pleural biopsies was performed before therapy and then after every two cycles. The primary end point was pathologic response as determined by thoracoscopic biopsy. RESULTS After at least two cycles, post-treatment pleural biopsy analysis was negative in 14 patients for a pathologic response rate of 42% (95% CI, 25% to 61%). Median survival was 11.2 months. There were three treatment-related deaths secondary to peritonitis, cellulitis at the thoracoscopy site, and empyema. Grade 3 nonhematologic toxicities included infection, fever, dyspnea, and anorexia, which occurred in five (15%), one (3%), one (3%), and one (3%) patients, respectively. There were no grade 4 nonhematologic toxicities. Grade 3 or 4 neutropenia, thrombocytopenia, and anemia occurred in five (15%), three (9%), and two (6%) patients, respectively. Two patients with pathologic responses subsequently underwent pleural decortication. Both surgical specimens revealed residual tumor in regions that were not in direct communication with the pleural space. CONCLUSION Intrapleural L-NDDP therapy in this patient population is feasible with significant but manageable toxicity. Although pathologic responses are highly encouraging, areas of mesothelioma that are not in direct communication with the pleural space will evade drug exposure and limit efficacy in some patients. The optimal role of intrapleural L-NDDP therapy currently remains to be determined.
This paper references
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1053/SONC.2002.30231
Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine.
P. Baas (2002)
10.1007/S11912-003-0076-9
Advances in the management of malignant mesothelioma
Mazen Y. Khalil (2003)
10.1016/j.hoc.2005.09.004
Gene therapy for malignant pleural mesothelioma.
D. Sterman (1998)
10.1016/0305-7372(89)90011-X
Liposomes as carriers of antitumor agents: toward a clinical reality.
R. Pérez-Soler (1989)
10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3
Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma
P. Astoul (1998)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1007/s00432-003-0481-3
Phase I clinical and pharmacological study of intraperitoneal cis-bis-neodecanoato(trans-R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar liposome vesicles
C. Verschraegen (2003)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1016/S0169-5002(00)00192-6
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
B. Castagneto (2001)
10.1200/JCO.2003.06.122
Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
G. Scagliotti (2003)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) encapsulated in multilamellar vesicles.
R. Pérez-Soler (1987)
Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in multilamellar lipid vesicles.
R. Pérez-Soler (1988)
10.1007/BF00689964
Pharmacokinetics of liposome-entrappedcis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat
K. Vadiei (2004)
10.3816/CLC.2003.N.023
Chemotherapy for malignant pleural mesothelioma.
P. Jänne (2003)
10.1177/030089169608200111
Surgery Followed by Intracavitary plus Systemic Chemotherapy in Malignant Pleural Mesothelioma
M. Colleoni (1996)
Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II).
R. Pérez-Soler (1990)
10.1016/J.LUNGCAN.2003.09.021
Staging and evaluating responses in malignant pleural mesothelioma.
G. Hillerdal (2004)
10.3109/02652049409040437
Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use.
R. Perez-soler (1994)
Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
R. Pérez-Soler (1997)
10.1093/OXFORDJOURNALS.AJE.A009093
Analysis of current trends in United States mesothelioma incidence.
B. Price (1997)
10.1053/SONC.2002.30237
The epidemiology of mesothelioma.
M. Britton (2002)
10.1002/JSO.2930600410
Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: The ucla experience
J. D. Lee (1995)
10.1053/SONC.2002.30230
Multimodality treatment of diffuse malignant pleural mesothelioma.
L. Zellos (2002)
10.1016/0021-9681(61)90060-1
The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent.
E. Gehan (1961)
10.1093/JNCI/78.6.1053
Demographic patterns for mesothelioma in the United States.
R. Connelly (1987)



This paper is referenced by
10.1007/978-0-387-76554-9_10
Multifunctional Nanotherapeutics for Cancer
T. Minko (2008)
10.1039/c0dt00292e
The status of platinum anticancer drugs in the clinic and in clinical trials.
Nial J. Wheate (2010)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
10.1007/978-1-60327-360-2_1
Current trends in liposome research.
T. Elbayoumi (2010)
10.1016/J.CCR.2013.04.014
Nano-functionalization of metal complexes for molecular imaging and anticancer therapy
C. Maldonado (2013)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1016/j.jtcvs.2007.10.026
Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma.
Masaki Anraku (2008)
10.1088/1742-6596/1310/1/012011
A study on the physicochemical properties and cytotoxic activity of p-sulfocalix[4]arene-nedaplatin complex
Sherif Ashraf Fahmy (2019)
10.1517/13543776.16.10.1383
Recent developments in antitumour platinum coordination compounds
G. Momekov (2006)
10.1016/j.nano.2018.05.021
Lipid based nanocarriers: a translational perspective.
D. Mishra (2018)
10.1002/wnan.1390
Nanoparticle formulations of cisplatin for cancer therapy.
X. Duan (2016)
10.1007/s12032-010-9541-0
The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib
Y. Zhao (2011)
10.1016/J.CCR.2016.01.001
Nanostructured materials functionalized with metal complexes: In search of alternatives for administering anticancer metallodrugs
W. A. Wani (2016)
10.1039/b912708a
Novel and emerging approaches for the delivery of metallo-drugs.
Carlos Sanchez-Cano (2009)
10.1016/J.ICA.2012.06.005
Metallo-drugs in the treatment of malignant pleural mesothelioma
I. Zanellato (2012)
10.1002/psc.2481
Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery
A. Accardo (2013)
10.1016/j.drudis.2011.09.015
Liposomal drug formulations in cancer therapy: 15 years along the road.
M. Slingerland (2012)
10.1124/pr.115.012070
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Phatsapong Yingchoncharoen (2016)
10.1016/j.jtcvs.2007.10.054
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.
R. Flores (2008)
10.1002/9783527645787.CH10
New Directions in the Fight against Cancer: From Metal Complexes to Nanostructured Materials
S. Gómez-Ruiz (2012)
10.1002/jps.21358
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.
D. Drummond (2008)
10.1183/09031936.00090407
Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1α
C. Riganti (2008)
10.1002/9783527610419.NTLS0066
Critical Analysis of Cancer Therapy using Nanomaterials
L. Juillerat-Jeanneret (2007)
10.1053/j.semtcvs.2009.06.008
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication.
R. Flores (2009)
10.1016/J.AJPS.2013.07.010
Development of liposomal formulations: From concept to clinical investigations
Yuchen Fan (2013)
10.1016/j.biomaterials.2010.11.073
The effect of internalizing human single chain antibody fragment on liposome targeting to epithelioid and sarcomatoid mesothelioma.
A. Iyer (2011)
10.1016/j.jinorgbio.2008.12.011
Side-on binding of p-sulphonatocalix[4]arene to the dinuclear platinum complex trans-[{PtCl(NH3)2}2mu-dpzm]2+ and its implications for anticancer drug delivery.
N. Wheate (2009)
10.1007/s11864-014-0314-4
Local and Systemic Therapies for Malignant Pleural Mesothelioma
D. Gomez (2014)
10.1016/j.jaci.2007.12.1167
Not miR-ly small RNAs: big potential for microRNAs in therapy.
T. Love (2008)
10.1016/j.ejpb.2015.03.018
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Edgar Pérez-Herrero (2015)
10.2147/IJN.S237536
The Safety and Exploration of the Pharmacokinetics of Intrapleural Liposomal Curcumin
A. Hocking (2020)
10.2217/17435889.1.3.297
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
M. Immordino (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar